Use of topical ketanserin in the treatment of skin ulcers: a double-blind study. 1989

P A Janssen, and H Janssen, and G Cauwenbergh, and P De Doncker, and K De Beule, and P Lewi, and H F Tytgat, and C M Lapière
Janssen Research Foundation, Beerse, Belgium.

The use of a 2% ointment formulation of ketanserin, an S2-serotoninergic blocking agent, was investigated in a randomized double-blind clinical trial for its effect on the healing of wounds of patients with decubitus, venous, and ischemic skin ulcers. The result demonstrates a significant difference in favor of the ketanserin-treated group (35 patients) versus the placebo-treated group (37 patients) on the basis of two factors: formation of granulation tissue and epithelialization. In addition, a significant difference of 150% in the initial velocity of wound closure was observed in favor of the patients treated with ketanserin. This effect was persistent during the entire study period.

UI MeSH Term Description Entries
D007511 Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. Ischemias
D007650 Ketanserin A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients. 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione,R-41,468,R-41468,R 41,468,R 41468,R41,468,R41468
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D003668 Pressure Ulcer An ulceration caused by prolonged pressure on the SKIN and TISSUES when one stays in one position for a long period of time, such as lying in bed. The bony areas of the body are the most frequently affected sites which become ischemic (ISCHEMIA) under sustained and constant pressure. Bedsore,Decubitus Sore,Decubitus Ulcer,Pressure Injury,Pressure Sore,Bed Sores,Bed Sore,Bedsores,Decubitus Sores,Decubitus Ulcers,Injury, Pressure,Pressure Injuries,Pressure Sores,Pressure Ulcers,Sore, Bed,Sore, Decubitus,Sore, Pressure,Ulcer, Decubitus,Ulcer, Pressure
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P A Janssen, and H Janssen, and G Cauwenbergh, and P De Doncker, and K De Beule, and P Lewi, and H F Tytgat, and C M Lapière
January 1989, Dermatologica,
P A Janssen, and H Janssen, and G Cauwenbergh, and P De Doncker, and K De Beule, and P Lewi, and H F Tytgat, and C M Lapière
January 2001, Indian journal of leprosy,
P A Janssen, and H Janssen, and G Cauwenbergh, and P De Doncker, and K De Beule, and P Lewi, and H F Tytgat, and C M Lapière
November 2001, Indian journal of medical sciences,
P A Janssen, and H Janssen, and G Cauwenbergh, and P De Doncker, and K De Beule, and P Lewi, and H F Tytgat, and C M Lapière
January 1958, Antibiotics annual,
P A Janssen, and H Janssen, and G Cauwenbergh, and P De Doncker, and K De Beule, and P Lewi, and H F Tytgat, and C M Lapière
September 1994, Prostaglandins, leukotrienes, and essential fatty acids,
P A Janssen, and H Janssen, and G Cauwenbergh, and P De Doncker, and K De Beule, and P Lewi, and H F Tytgat, and C M Lapière
January 1997, Archives of medical research,
P A Janssen, and H Janssen, and G Cauwenbergh, and P De Doncker, and K De Beule, and P Lewi, and H F Tytgat, and C M Lapière
January 1989, International angiology : a journal of the International Union of Angiology,
P A Janssen, and H Janssen, and G Cauwenbergh, and P De Doncker, and K De Beule, and P Lewi, and H F Tytgat, and C M Lapière
July 1985, Postgraduate medical journal,
P A Janssen, and H Janssen, and G Cauwenbergh, and P De Doncker, and K De Beule, and P Lewi, and H F Tytgat, and C M Lapière
February 1989, The British journal of dermatology,
P A Janssen, and H Janssen, and G Cauwenbergh, and P De Doncker, and K De Beule, and P Lewi, and H F Tytgat, and C M Lapière
January 1988, JAMA,
Copied contents to your clipboard!